(Montisera, Raisio, Finland; 16 January 2017) – Montisera Ltd, a Finnish development company focused on developing and commercialising bioactive compounds, has successfully closed Seed A round of €0.3 million. The company also announced that the Seed B round has started, in which Montisera aims to collect € 0.7 million, share price being 200 € per share.
“The Seed capital will be used to finalise the preclinical steps for both of our main two assets, namely Montisera_D15, our novel CNS molecule, and Montisera_D4, an extract from Spruce for the prevention and treatment of lower urinary tract diseases.”, says Mira Povelainen, CEO of Montisera.
The Seed B round is now open for the existing and new shareholders. More information about the round can be found from the company web pages at www.montisera.com.
For further information please contact:
Mira Povelainen, CEO, tel. +358 40 578 9692
Founded in 2012, Montisera is a privately owned Finnish development company focused on discovering, developing and commercialising bioactive compounds from its development platform to be used in novel products in the pharmaceutical and food industries. Montisera’s focus is on the management of its global partner network of universities, science companies, laboratories, contract research organisations (CROs) , etc. Montisera currently has three bioactive compounds in its development platform in different stages of the development pipeline, ranging from Parkinson’s disease to alcoholism and lower urinary tract diseases.